NEW YORK (GenomeWeb) – Cell-and bead-based screening technologies firm IntelliCyt has closed a $2.5 million secured term loan agreement and a $1.5 million revolving line of credit from Oxford Finance, the financing firm announced today.
Albuquerque, NM-based IntelliCyt will use the debt facility for working capital, as well as product development and marketing. The company develops high-throughput, high-content screening products for phenotypic drug discovery, antibody discovery, and in vivo toxicity testing.
IntelliCyt raised $8 million in a financing round last year.